Literature DB >> 31522159

Clinical and Radiographic Assessment of Single or Combined Treatment with Lepidium sativum and Alendronate of Non-Surgically Treated Chronic Periodontitis in Postmenopausal Osteoporotic Women.

Naglaa Shawki El Kilani1, Hala Helmy Hazzaa2, Hisham El Sayed Hemoud3, Omenya Imam2.   

Abstract

AIM OF THE STUDY: The aim of the study was to compare the clinical outcomes, radiometric indices (antigonial index and mental index) before and after nonsurgical treatment of chronic periodontitis in postmenopausal osteoporotic women receiving alendronate (ALN) and Lepidium sativum either singly or combined.
MATERIALS AND METHODS: The study was conducted on 45 postmenopausal osteoporotic women with chronic periodontitis. The study population was divided randomly and equally into three groups: A, B and C (15 patients each). Group A: local debridement was performed for these patients. They received ALN at a dose of (70 mg/ once/ week) for six months as regular treatment of osteoporosis. Group B: patients were given finely powdered dried seeds of Lepidium sativum (LS; 1 gm tid) for six weeks plus local debridement. Group C: patients received combined treatment of LS at a dose of 1 gm/tid (for six weeks) and ALN at a dose of 70 mg once weekly for six months plus local debridement. Gingival index (GI), pocket depth (PI) and clinical attachment level (CAL) were measured together with ADAM8 level in the GSF of the study group at baseline, three and six months.
RESULTS: By comparing the means of GI at baseline, three months and six months within the three groups, Group C showed the highest signifi cant decrease in the mean GI (p = 0.01). Comparing the pocket depth and the clinical attachment level, Group B and C showed comparable pocket depth reduction and Group C reported the highest clinical attachment gain at p=0.001. By comparing the mean of radiometric indices of the three groups through the whole study period, Group C showed the greatest increase in the MI index from baseline to six months at p=0.0001. By comparing the mean percentage of change (%) in GI among the three groups, Group C showed the statistically signifi cant highest mean percent decrease in GI. By comparing the mean percentage of change of pocket depth before and after treatment, both Groups B and C showed significantly higher percentage of PD reduction than Group A after three months and six months at p = 0.002 and p = 0.001, respectively, while no signifi cant difference was detected between groups B and C through the whole study period. By comparing mean percentage of changes of CAL, Group C showed the highest percentage of CAL change.
CONCLUSIONS: Within the limits of the study, it is concluded that Lepidium sativum can be used in the treatment of osteoporotic postmenopausal women with chronic periodontitis who refuse treatment with ALN. The combined use of LS and ALN may have a synergistic effect resulting in a more favorable clinical response, increased bone mass than using ALN alone when combined with conventional therapy in treatment of chronic periodontitis in postmenopausal osteoporotic women. Copyright© by the International Academy of Periodontology.

Entities:  

Keywords:  Lepidium sativum; host modulation; osteoporosis; periodontitis; radiomorphometric indices

Mesh:

Substances:

Year:  2019        PMID: 31522159

Source DB:  PubMed          Journal:  J Int Acad Periodontol        ISSN: 1466-2094


  2 in total

1.  Osteoprotective Activity and Metabolite Fingerprint via UPLC/MS and GC/MS of Lepidium sativum in Ovariectomized Rats.

Authors:  Hossam M Abdallah; Mohamed A Farag; Mardi M Algandaby; Mohammed Z Nasrullah; Ashraf B Abdel-Naim; Basma G Eid; Martin K Safo; Abdulrahman E Koshak; Azizah M Malebari
Journal:  Nutrients       Date:  2020-07-13       Impact factor: 5.717

2.  Effect of systemic bisphosphonate administration on patients with periodontal disease: a systematic review and meta-analysis protocol.

Authors:  Yoko Koide; Yu Kataoka; Takeshi Hasegawa; Erika Ota; Hisashi Noma
Journal:  BMJ Open       Date:  2022-03-04       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.